Gupta-Wright A, den Boon S, MacLean E, Cirillo DM, Cobelens F, et al.
2023-11-01 • Bulletin of the World Health Organization
2023-11-01 • Bulletin of the World Health Organization
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and opt...
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, et al.
2020-03-20 • European Respiratory Journal
2020-03-20 • European Respiratory Journal
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...
The environmental adversities around the Aral Sea in Central Asia have been the subject of recent research. Attempts at sustainable provision of palatable drinking water in low chemical ...
Muntean N, Jermini M, Small I, Falzon D, Fürst P, et al.
2003-08-01 • Environmental Health Perspectives
2003-08-01 • Environmental Health Perspectives
A 1999 study heightened long-standing concerns over persistent organic pollutant contamination in the Aral Sea area, detecting elevated levels in breast milk and cord blood of women in K...
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J, et al.
2012-08-28 • PLOS Medicine
2012-08-28 • PLOS Medicine
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the ...
Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, et al.
2016-09-01 • European Respiratory Journal
2016-09-01 • European Respiratory Journal
Debate persists about monitoring method (culture or smear) and interval (monthly or less frequently) during treatment for multidrug-resistant tuberculosis (MDR-TB). We analysed existing ...
Khaliaukin A, Kumar AMV, Skrahina A, Hurevich H, Rusovich V, et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTINGS Tuberculosis (TB) health facilities in the Gomel Region, Republic of Belarus-settings with a high burden of multidrug-resistant TB (MDR-TB) and human immunodeficiency virus ...
Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, et al.
2018-07-11 • PLOS Medicine
2018-07-11 • PLOS Medicine
An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optima...
Lonnroth K, Migliori GB, Abubakar I, DAmbrosio L, de Vries G, et al.
2015-03-18 • European Respiratory Journal
2015-03-18 • European Respiratory Journal
This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination. The framework set...
Trauer JM, Achar J, Parpieva N, Khamraev AK, Denholm JT, et al.
2016-11-18 • BMC Medicine
2016-11-18 • BMC Medicine
BACKGROUND Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and o...
Cox HS, Orozco JD , Male R, Rüsch-Gerdes S, Falzon D, et al.
2004-05-01 • Emerging Infectious Diseases
2004-05-01 • Emerging Infectious Diseases
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly o...
